KCT0008186已完成未知
An 8-week, multi-center, randomized, double-blinded, placebo-controlled study of YHC-BE-2040 to evaluate efficacy and safety on immune function
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 40(Year) 至 70(Year)（—）
- 性别
- All
入选标准
- •1. Men and women over 40 and under 70
- •2. Those with a white blood cell count of 4.0×10^3 cells/µl or more and 8.0×10^3 cells/µl or less
- •3. A person who has given written consent to the human body application test consent form
- •4. Those who had symptoms of upper respiratory tract infection (cold, tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, rhinitis, etc.) two or more times within one year before the start of the test
排除标准
- •1. Subjects who have experienced adverse reactions such as hypersensitivity and allergy when taking health functional foods and medicines, including deer velvet extract
- •2. Subjects whose BMI is less than 18.5 kg/m^2 or greater than 30.0 kg/m^2
- •3. Subjects with immune-related diseases such as liver disease including active hepatitis, leukemia, inflammatory systemic diseases, infectious diseases, and autoimmune diseases
- •4. Subjects who have been diagnosed with dementia, brain tumor, or hydrocephalus, or have undergone or are receiving hormone replacement therapy within the last 4 weeks
- •5. Patients with stroke, heart disease (heart failure, arrhythmia, angina pectoris, myocardial infarction, history of pacemaker use), malignant tumor, narrow angle glaucoma, uncontrolled hypertension (SBP 140 mmHg or higher or DBP 90 mmHg or higher), or lung Patients with diseases or respiratory diseases
- •6. Subjects with severe renal dysfunction (eGFR <60 mL/min/1.73^2) or liver dysfunction (ALT, AST, ALP> upper limit of normal × 2.5)
- •7. If blood sugar control is difficult with hypoglycemic agents (despite taking hypoglycemic agents, fasting blood sugar 160mg/dl or higher) and subjects receiving insulin injections)
- •8. Persons with a platelet count of 100×10^3/µl or less
- •9. Those who have started taking oral steroids, hormones, etc. within the last 4 weeks, or have experienced taking drugs that affect the absorption, metabolism, and excretion of the test food
- •10. Those who have participated in other clinical trials or human application trials within the last 6 months
- •11. A person who has undergone a surgical operation within the last 6 months or has been receiving prohibited treatment within 4 weeks (health food for the purpose of strengthening immunity, herbal medicine, or drug that is likely to be abused)
- •12. Subjects who have undergone gastrointestinal dysfunction or surgery that may affect drug absorption, such as gastrectomy
- •13. Subjects with thyroid disease (thyroid or hormone abnormalities/abnormal thyroid levels)
- •14. Neuropsychiatric disorders (depression, schizophrenia), subjects who received psychological treatment
- •15. Subjects who have undergone surgery (including childbirth) within the last 6 months or are cancer patients
- •16. Drug addicts and those who have been vaccinated against influenza within the past 3 months, those who have taken immunosuppressants, non-steroidal anti-inflammatory drugs, steroid drugs, antihistamines, and antibiotics
- •17. Pregnant and lactating women and women of childbearing potential who disagree with the choice of an appropriate method of contraception (oral contraceptives, hormone implants, intrauterine devices, condoms, spermicides)
- •18. Subjects who have received a COVID-19 vaccine within the last 4 weeks, have taken immunosuppressants, or have taken other immune-improving functional foods
- •19. Whole blood donation within the last 2 months or component blood donation within 4 weeks
- •20. Subjects judged to be unable to comply with the requirements of the study or unsuitable for participation in this study, in the opinion of the study director (or the commissioned investigator
研究者
相似试验
进行中（未招募）
不适用
An 8-week, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of Diclofenac Sodium Gel 1% in patients with primary osteoarthritis of the hand - N/APrimary osteoarthritis of the hand.MedDRA version: 7.1Level: LLTClassification code 10058192EUCTR2004-004776-37-DEovartis Consumer Health S.A.360
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amoldipine in patients with essential hypertension - NDEssential hypertensionMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2008-001609-40-ITOVARTIS FARMA1,611
已完成
不适用
Efficacy and safety of Hwangchil-unripe Bokbunja Extract Mixtures on blood pressureKCT0004300Wonkwang University Oriental Medical Hospital, Jeonju88
进行中（未招募）
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertensionEUCTR2006-000774-70-GBovartis Pharma Services AG2,252
进行中（未招募）
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertensionEUCTR2006-000774-70-SEovartis Pharma Services AG2,252